Refine
Year of publication
Document Type
- Preprint (576)
- Article (391)
- Book (1)
- Part of a Book (1)
- Conference Proceeding (1)
- Diploma Thesis (1)
- Working Paper (1)
Has Fulltext
- yes (972)
Is part of the Bibliography
- no (972)
Keywords
- Heavy Ion Experiments (18)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Atmospheric chemistry (4)
- Hadron-Hadron Scattering (4)
- Heavy Ions (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Jets and Jet Substructure (3)
- pp collisions (3)
- Atmospheric science (2)
- Beauty production (2)
- COVID-19 (2)
- Charm physics (2)
- Climate change (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Jets (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- SARS-CoV-2 (2)
- Single electrons (2)
- 900 GeV (1)
- AKI (1)
- ALICE detector (1)
- Actin (1)
- Acute myeloid leukaemia (1)
- Anti-nuclei (1)
- Atomic and Molecular Physics (1)
- B cell receptor (1)
- Biogeochemistry (1)
- Biomarkers (1)
- CD14 (1)
- CD16 (1)
- CD47 (1)
- CD62L (1)
- CLOUD experiment (1)
- COMT (1)
- COVID 19 (1)
- CVID (1)
- Calorimeters (1)
- Cardiac surgery (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Centrality Class (1)
- Centrality Selection (1)
- Chemical composition (1)
- Climate-change impacts (1)
- Collective Flow (1)
- Comparison with QCD (1)
- Completed suicide (1)
- Consensus (1)
- Datenbanksystem (1)
- Demolition emissions (1)
- Dilated cardiomyopathy (1)
- Direct reactions (1)
- Drug screens (1)
- ER stress (1)
- Ehe <Motiv> (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Endothelial cells (1)
- Erzählperspektive (1)
- European Society for Immunodeficiencies (ESID) (1)
- European registry for idiopathic pulmonary fibrosis (eurIPFreg) (1)
- Evidence-based (1)
- Evidenzbasierung (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- German PID-NET registry (1)
- Guidelines (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Heart (1)
- Heavy Ion Experiment (1)
- Heavy Quark Production (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hematology (1)
- Heterogenität (1)
- High-energy neutron detection (1)
- Hypertension (1)
- IAP (1)
- Idiopathic pulmonary fibrosis (IPF) (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Inflammation (1)
- Intensity interferometry (1)
- Interstitial lung diseases (ILD) (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jean / Siebenkäs (1)
- Johann Wolfgang von Goethe (1)
- KDIGO (1)
- Kongress (1)
- Konsens (1)
- Korpusannotation (1)
- Leitlinien (1)
- Leukemias (1)
- Mehrsprachigkeit (1)
- Mena/VASP (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Molecularly targeted therapy (1)
- Monte Carlo (1)
- Multi-neutron detection (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Myelodysplastic syndrome (1)
- Neural network (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- Oncology (1)
- PID prevalence (1)
- PM10 (1)
- PMA (1)
- PYTHIA (1)
- Pandemic (1)
- Particle Correlations and Fluctuations (1)
- Pb–Pb (1)
- Performance of High Energy Physics Detectors (1)
- Phase I trials (1)
- Plastic scintillator array (1)
- Postvention (1)
- Potsdam <2004> (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton–proton (1)
- QCD (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Rapidity Range (1)
- Reactions with relativistic radioactive beams (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- SARS CoV 2 (1)
- SARS-CoV2 (1)
- SIRPalpha (1)
- Shell model (1)
- Single muons (1)
- Size distribution (1)
- Spectrin (1)
- Spectroscopic factors & electromagnetic moments (1)
- Sprachdaten (1)
- Stem-cell therapies (1)
- Suicidality (1)
- Suicide attempt (1)
- Suizidalität (1)
- Systematic Uncertainty (1)
- TR (1)
- TUSNELDA (1)
- TUSNELDA-Standard (1)
- Thermodynamics (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Ultrafine particles (1)
- Urban aerosol (1)
- Vector Boson Production (1)
- Virus trapping (1)
- Xenon-based gas mixture (1)
- aerosol formation (1)
- aerosols (1)
- antiviral therapy (1)
- binary nucleation (1)
- complications (1)
- coronavirus (1)
- dE/dx (1)
- fMLP (1)
- heavy ion experiments (1)
- ion‐induced nucleation (1)
- loss of signal (1)
- nanoparticle growth (1)
- phagocytosis (1)
- primary immunodeficiency (PID) (1)
- quark gluon plasma (1)
- reactive oxygen species (1)
- registry for primary immunodeficiency (1)
- spectra (1)
- speech tagging (1)
- thyroid surgery (1)
- traumatic injury (1)
- vocal cord dysfunction (1)
- vocal cord palsy (1)
- volatile organic compounds (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (916)
- Frankfurt Institute for Advanced Studies (FIAS) (835)
- Informatik (801)
- Medizin (22)
- Geowissenschaften (21)
- ELEMENTS (6)
- Extern (4)
- Geowissenschaften / Geographie (3)
- Informatik und Mathematik (3)
- Starker Start ins Studium: Qualitätspakt Lehre (3)
The ALICE experiment has measured the inclusive J/ψ production in Pb-Pb collisions at sNN−−−√=2.76 TeV down to zero transverse momentum in the rapidity range 2.5<y<4. A suppression of the inclusive J/ψ yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0-80% most central collisions, is 0.545±0.032(stat.)±0.083(syst.) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from measurements at lower collision energies. Models including J/ψ production from charm quarks in a deconfined partonic phase can describe our data.
The ALICE experiment has measured the inclusive J/psi production in Pb-Pb collisions at sqrt(sNN) = 2.76 TeV down to zero transverse momentum in the rapidity range 2.5 < y < 4. A suppression of the inclusive J/psi yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0%-80% most central collisions, is 0.545+/-0.032(stat)+/-0.083(syst) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from measurements at lower collision energies. Models including J/psi production from charm quarks in a deconfined partonic phase can describe our data.
The ALICE experiment has measured the inclusive J/ψ production in Pb-Pb collisions at sNN−−−√=2.76 TeV down to zero transverse momentum in the rapidity range 2.5<y<4. A suppression of the inclusive J/ψ yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0-80% most central collisions, is 0.545±0.032(stat.)±0.083(syst.) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from measurements at lower collision energies. Models including J/ψ production from charm quarks in a deconfined partonic phase can describe our data.
The ALICE experiment has measured the inclusive J/psi production in Pb-Pb collisions at sqrt(sNN) = 2.76 TeV down to pt = 0 in the rapidity range 2.5 < y < 4. A suppression of the inclusive J/psi yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0%-80% most central collisions, is 0.545 +/- 0.032 (stat.) +/- 0.084 (syst.) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from lower energy measurements. Models including J/psi production from charm quarks in a deconfined partonic phase can describe our data.
Aims: Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system (RAAS) were suspected to influence disease severity.
Methods and results: We analyzed 1946 consecutive patients with cardiovascular comorbidities or hypertension enrolled in one of the largest European COVID-19 registries, the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry. Here, we show that angiotensin II receptor blocker intake is associated with decreased mortality in patients with COVID-19 [OR 0.75 (95% CI 0,59–0.96; p = 0.013)]. This effect was mainly driven by patients, who presented in an early phase of COVID-19 at baseline [OR 0,64 (95% CI 0,43–0,96; p = 0.029)]. Kaplan-Meier analysis revealed a significantly lower incidence of death in patients on an angiotensin receptor blocker (ARB) (n = 33/318;10,4%) compared to patients using an angiotensin-converting enzyme inhibitor (ACEi) (n = 60/348;17,2%) or patients who received neither an ACE-inhibitor nor an ARB at baseline in the uncomplicated phase (n = 90/466; 19,3%; p<0.034). Patients taking an ARB were significantly less frequently reaching the mortality predicting threshold for leukocytes (p<0.001), neutrophils (p = 0.002) and the inflammatory markers CRP (p = 0.021), procalcitonin (p = 0.001) and IL-6 (p = 0.049). ACE2 expression levels in human lung samples were not altered in patients taking RAAS modulators.
Conclusion: These data suggest a beneficial effect of ARBs on disease severity in patients with cardiovascular comorbidities and COVID-19, which is linked to dampened systemic inflammatory activity.
Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect on symptom reduction and on general well being of patients suffering from psychosis. However, questions regarding the specific efficacy of CBT, the treatment safety, the cost-effectiveness, and the moderators and mediators of treatment effects are still a major issue. The major objective of this trial is to investigate whether CBT is specifically efficacious in reducing positive symptoms when compared with non-specific supportive therapy (ST) which does not implement CBT-techniques but provides comparable therapeutic attention. Methods: The POSITIVE study is a multicenter, prospective, single-blind, parallel group, randomised clinical trial, comparing CBT and ST with respect to the efficacy in reducing positive symptoms in psychotic disorders. CBT as well as ST consist of 20 sessions altogether, 165 participants receiving CBT and 165 participants receiving ST. Major methodological aspects of the study are systematic recruitment, explicit inclusion criteria, reliability checks of assessments with control for rater shift, analysis by intention to treat, data management using remote data entry, measures of quality assurance (e.g. on-site monitoring with source data verification, regular query process), advanced statistical analysis, manualized treatment, checks of adherence and competence of therapists. Research relating the psychotherapy process with outcome, neurobiological research addressing basic questions of delusion formation using fMRI and neuropsychological assessment and treatment research investigating adaptations of CBT for adolescents is combined in this network. Problems of transfer into routine clinical care will be identified and addressed by a project focusing on cost efficiency. Discussion: This clinical trial is part of efforts to intensify psychotherapy research in the field of psychosis in Germany, to contribute to the international discussion on psychotherapy in psychotic disorders, and to help implement psychotherapy in routine care. Furthermore, the study will allow drawing conclusions about the mediators of treatment effects of CBT of psychotic disorders. Trial Registration Current Controlled Trials ISRCTN29242879
Non-standard errors
(2021)
In statistics, samples are drawn from a population in a data-generating process (DGP). Standard errors measure the uncertainty in sample estimates of population parameters. In science, evidence is generated to test hypotheses in an evidence-generating process (EGP). We claim that EGP variation across researchers adds uncertainty: non-standard errors. To study them, we let 164 teams test six hypotheses on the same sample. We find that non-standard errors are sizeable, on par with standard errors. Their size (i) co-varies only weakly with team merits, reproducibility, or peer rating, (ii) declines significantly after peer-feedback, and (iii) is underestimated by participants.
The nucleosynthesis of elements beyond iron is dominated by neutron captures in the s and r processes. However, 32 stable, proton-rich isotopes cannot be formed during those processes, because they are shielded from the s-process flow and r-process β-decay chains. These nuclei are attributed to the p and rp process.
For all those processes, current research in nuclear astrophysics addresses the need for more precise reaction data involving radioactive isotopes. Depending on the particular reaction, direct or inverse kinematics, forward or time-reversed direction are investigated to determine or at least to constrain the desired reaction cross sections.
The Facility for Antiproton and Ion Research (FAIR) will offer unique, unprecedented opportunities to investigate many of the important reactions. The high yield of radioactive isotopes, even far away from the valley of stability, allows the investigation of isotopes involved in processes as exotic as the r or rp processes.
Der TUSNELDA-Standard : ein Korpusannotierungsstandard zur Unterstützung linguistischer Forschung
(2001)
Die Verwendung von Standards für die Annotierung größerer Sammlungen elektronischer Texte (Korpora) ist eine Voraussetzung für eine mögliche Wiederverwendung dieser Korpora. Dieser Artikel stellt einen Korpusannotierungsstandard vor, der die Anforderungen der Untersuchung unterschiedlichster linguistischer Phänomene berücksichtigt. Der Standard wurde im SFB 441 an der Universität Tübingen entwickelt. Er geht von bestehenden Standards, insbesondere CES und TEI, aus, die sich als teilweise zu ausführlich und zu wenig restriktiv,teilweise auch als nicht ausdrucksstark genug erweisen, um den Bedürfnissen korpusbasierter linguistischer Forschung gerecht zu werden.